Translational medicine in action: Anti-CD20 therapy in Lymphoma

Journal of Immunology

Volumn 193, Issue 4, 2014, Pages 1519-1524

  Lim, Sean H ^a   Levy, Ronald ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; CD20 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FC RECEPTOR IIA; FC RECEPTOR IIB; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD20; OBINUTUZUMAB; OFATUMUMAB; PREDNISONE; RITUXIMAB; TOSITUMOMAB; UNCLASSIFIED DRUG; VINCRISTINE;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS B; HUMAN; LYMPHOMA; MAINTENANCE THERAPY; MONOTHERAPY; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN EXPRESSION; TRANSLATIONAL RESEARCH; TREATMENT OUTCOME; VIRUS REACTIVATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOGLOBULIN IDIOTYPES; IMMUNOLOGIC FACTORS; LYMPHOMA, B-CELL; MOLECULAR TARGETED THERAPY; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84905972726     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1490027     Document Type: Article

References (73)

1. American Cancer Society. 2013. Cancer Facts & Figures 2013. American Cancer Society, Atlanta, GA.
2. Fisher, R. I., E. R. Gaynor, S. Dahlberg, M. M. Oken, T. M. Grogan, E. M. Mize, J. H. Glick, C. A. Coltman, Jr, and T. P. Miller. 1993. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N. Engl. J. Med. 328: 1002-1006.
3. Fjermedal, G. 1984. Magic Bullets. Macmillan, New York.
4. Klinman, N. R. 1971. Purification and analysis of "monofocal" antibody. J. Immunol. 106: 1345-1352.
5. Köhler, G., and C. Milstein. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495-497.
6. Stevenson, G. T., and F. K. Stevenson. 1975. Antibody to a molecularly-defined antigen confined to a tumour cell surface. Nature 254: 714-716.
7. Hatzubai, A., D. G. Maloney, and R. Levy. 1981. The use of a monoclonal antiidiotype antibody to study the biology of a human B cell lymphoma. J. Immunol. 126: 2397-2402.
8. Miller, R. A., D. G. Maloney, R. Warnke, and R. Levy. 1982. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N. Engl. J. Med. 306: 517-522.
9. Maloney, D. G., S. Brown, D. K. Czerwinski, T. M. Liles, S. M. Hart, R. A. Miller, and R. Levy. 1992. Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: The addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells. Blood 80: 1502-1510.
10. Davis, T. A., D. G. Maloney, D. K. Czerwinski, T. M. Liles, and R. Levy. 1998. Antiidiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. Blood 92: 1184-1190.
11. Nadler, L. M., P. Stashenko, R. Hardy, W. D. Kaplan, L. N. Button, D. W. Kufe, K. H. Antman, and S. F. Schlossman. 1980. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res. 40: 3147-3154.
12. Stashenko, P., L. M. Nadler, R. Hardy, and S. F. Schlossman. 1980. Characterization of a human B lymphocyte-specific antigen. J. Immunol. 125: 1678-1685.
13. Miller, R. A., A. R. Oseroff, P. T. Stratte, and R. Levy. 1983. Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood 62: 988-995.
14. Dillman, R. O., D. L. Shawler, J. B. Dillman, and I. Royston. 1984. Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. J. Clin. Oncol. 2: 881-891.
15. Van Kroonenburgh, M. J., and E. K. Pauwels. 1988. Human immunological response to mouse monoclonal antibodies in the treatment or diagnosis of malignant diseases. Nucl. Med. Commun. 9: 919-930.
16. Mirick, G. R., B. M. Bradt, S. J. Denardo, and G. L. Denardo. 2004. A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words. Q. J. Nucl. Med. Mol. Imaging 48: 251-257.
17. Morrison, S. L., M. J. Johnson, L. A. Herzenberg, and V. T. Oi. 1984. Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. USA 81: 6851-6855.
18. Reff, M. E., K. Carner, K. S. Chambers, P. C. Chinn, J. E. Leonard, R. Raab, R. A. Newman, N. Hanna, and D. R. Anderson. 1994. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83: 435-445.
19. Maloney, D. G., T. M. Liles, D. K. Czerwinski, C. Waldichuk, J. Rosenberg, A. Grillo-Lopez, and R. Levy. 1994. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84: 2457-2466.
20. Maloney, D. G., A. J. Grillo-López, C. A. White, D. Bodkin, R. J. Schilder, J. A. Neidhart, N. Janakiraman, K. A. Foon, T. M. Liles, B. K. Dallaire, et al. 1997. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90: 2188-2195.
21. McLaughlin, P., A. J. Grillo-López, B. K. Link, R. Levy, M. S. Czuczman, M. E. Williams, M. R. Heyman, I. Bence-Bruckler, C. A. White, F. Cabanillas, et al. 1998. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16: 2825-2833.
22. Czuczman, M. S., A. J. Grillo-López, C. A. White, M. Saleh, L. Gordon, A. F. LoBuglio, C. Jonas, D. Klippenstein, B. Dallaire, and C. Varns. 1999. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J. Clin. Oncol. 17: 268-276.
23. Coiffier, B., E. Lepage, J. Briere, R. Herbrecht, H. Tilly, R. Bouabdallah, P. Morel, E. Van Den Neste, G. Salles, P. Gaulard, et al. 2002. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346: 235-242.
24. Pfreundschuh, M., L. Trümper, A. Osterborg, R. Pettengell, M. Trneny, K. Imrie, D. Ma, D. Gill, J. Walewski, P. L. Zinzani, et al.; MabThera International Trial Group. 2006. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 7: 379-391.
25. Coiffier, B., C. Thieblemont, E. Van Den Neste, G. Lepeu, I. Plantier, S. Castaigne, S. Lefort, G. Marit, M. Macro, C. Sebban, et al. 2010. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d'Etudes des Lymphomes De l'Adulte. Blood 116: 2040-2045.
26. Pfreundschuh, M., E. Kuhnt, L. Trümper, A. Osterborg, M. Trneny, L. Shepherd, D. S. Gill, J. Walewski, R. Pettengell, U. Jaeger, et al.; MabThera International Trial (MInT) Group. 2011. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 12: 1013-1022.
27. Martinelli, G., S. F. Schmitz, U. Utiger, T. Cerny, U. Hess, S. Bassi, E. Okkinga, R. Stupp, R. Stahel, M. Heizmann, et al. 2010. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J. Clin. Oncol. 28: 4480-4484.
28. Marcus, R., K. Imrie, A. Belch, D. Cunningham, E. Flores, J. Catalano, P. Solal-Celigny, F. Offner, J. Walewski, J. Raposo, et al. 2005. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105: 1417-1423.
29. Hiddemann, W., M. Kneba, M. Dreyling, N. Schmitz, E. Lengfelder, R. Schmits, M. Reiser, B. Metzner, H. Harder, S. Hegewisch-Becker, et al. 2005. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106: 3725-3732.
30. Forstpointner, R., M. Dreyling, R. Repp, S. Hermann, A. Hänel, B. Metzner, C. Pott, F. Hartmann, F. Rothmann, R. Rohrberg, et al.; German Low-Grade Lymphoma Study Group. 2004. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104: 3064-3071.
31. Salles, G., J. F. Seymour, F. Offner, A. López-Guillermo, D. Belada, L. Xerri, P. Feugier, R. Bouabdallah, J. V. Catalano, P. Brice, et al. 2011. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial. Lancet 377: 42-51.
32. Salles, A., G. Seymour, P. Feugier, F. Offner, A. Lopez-Guillermo, D. Belada, L. Xerri, R. Bouabdallah, J. Catalano, B. Pauline, et al. 2013. Updated 6 year follow-up of the PRIMA Study confirms the benefit of 2-year rituximab mainte maintenance in follicular lymphoma patients responding to frontline immunochemotherapy. Blood 122: 509 (Abstr.).
33. Glennie, M. J., R. R. French, M. S. Cragg, and R. P. Taylor. 2007. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol. Immunol. 44: 3823-3837.
34. Lim, S. H., S. A. Beers, R. R. French, P. W. Johnson, M. J. Glennie, and M. S. Cragg. 2010. Anti-CD20 monoclonal antibodies: Historical and future perspectives. Haematologica 95: 135-143.
35. Cartron, G., L. Dacheux, G. Salles, P. Solal-Celigny, P. Bardos, P. Colombat, and H. Watier. 2002. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgRIIIa gene. Blood 99: 754-758.
36. Weng, W. K., and R. Levy. 2003. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21: 3940-3947.
37. Treon, S. P., M. Hansen, A. R. Branagan, S. Verselis, C. Emmanouilides, E. Kimby, S. R. Frankel, N. Touroutoglou, B. Turnbull, K. C. Anderson, et al. 2005. Polymorphisms in FcgRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia. J. Clin. Oncol. 23: 474-481.
38. Pedersen, I. M., A. M. Buhl, P. Klausen, C. H. Geisler, and J. Jurlander. 2002. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood 99: 1314-1319.
39. Bezombes, C., S. Grazide, C. Garret, C. Fabre, A. Quillet-Mary, S. Müller, J. P. Jaffrézou, and G. Laurent. 2004. Rituximab antiproliferative effect in Blymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood 104: 1166-1173.
40. Jazirehi, A. R., S. Huerta-Yepez, G. Cheng, and B. Bonavida. 2005. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factorkB signaling pathway in non-Hodgkin's lymphoma B-cell lines: Role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res. 65: 264-276.
41. Ivanov, A., S. A. Beers, C. A. Walshe, J. Honeychurch, W. Alduaij, K. L. Cox, K. N. Potter, S. Murray, C. H. Chan, T. Klymenko, et al. 2009. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J. Clin. Invest. 119: 2143-2159.
42. Selenko, N., O. Maidic, S. Draxier, A. Berer, U. Jäger, W. Knapp, and J. Stöckl. 2001. CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD81 cytotoxic T cells. Leukemia 15: 1619-1626.
43. Selenko, N., O. Majdic, U. Jäger, C. Sillaber, J. Stöckl, and W. Knapp. 2002. Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies? J. Clin. Immunol. 22: 124-130.
44. Chan, H. T., D. Hughes, R. R. French, A. L. Tutt, C. A. Walshe, J. L. Teeling, M. J. Glennie, and M. S. Cragg. 2003. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res. 63: 5480-5489.
45. Cragg, M. S., S. M. Morgan, H. T. Chan, B. P. Morgan, A. V. Filatov, P. W. Johnson, R. R. French, and M. J. Glennie. 2003. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 101: 1045-1052.
46. Cragg, M. S., and M. J. Glennie. 2004. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 103: 2738-2743.
47. Teeling, J. L., R. R. French, M. S. Cragg, J. Van Den Brakel, M. Pluyter, H. Huang, C. Chan, P. W. Parren, C. E. Hack, M. Dechant, et al. 2004. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104: 1793-1800.
48. Alduaij, W., A. Ivanov, J. Honeychurch, E. J. Cheadle, S. Potluri, S. H. Lim, K. Shimada, C. H. Chan, A. Tutt, S. A. Beers, et al. 2011. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood 117: 4519-4529.
49. Stolz, C., and M. Schuler. 2009. Molecular mechanisms of resistance to rituximab and pharmacologic strategies for its circumvention. Leuk. Lymphoma 50: 873-885.
50. Weng, W. K., and R. Levy. 2001. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood 98: 1352-1357.
51. Beum, P. V., A. D. Kennedy, and R. P. Taylor. 2004. Three new assays for rituximab based on its immunological activity or antigenic properties: Analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas. J. Immunol. Methods 289: 97-109.
52. Li, Y., M. E. Williams, J. B. Cousar, A. W. Pawluczkowycz, M. A. Lindorfer, and R. P. Taylor. 2007. Rituximab-CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models. J. Immunol. 179: 4263-4271.
53. Beum, P. V., E. M. Peek, M. A. Lindorfer, F. J. Beurskens, P. J. Engelberts, P. W. Parren, J. G. Van De Winkel, and R. P. Taylor. 2011. Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells. J. Immunol. 187: 3438-3447.
54. Kennedy, A. D., P. V. Beum, M. D. Solga, D. J. DiLillo, M. A. Lindorfer, C. E. Hess, J. J. Densmore, M. E. Williams, and R. P. Taylor. 2004. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J. Immunol. 172: 3280-3288.
55. Williams, M. E., J. J. Densmore, A. W. Pawluczkowycz, P. V. Beum, A. D. Kennedy, M. A. Lindorfer, S. H. Hamil, J. C. Eggleton, and R. P. Taylor. 2006. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J. Immunol. 177: 7435-7443.
56. O'Brien, S. M., H. Kantarjian, D. A. Thomas, F. J. Giles, E. J. Freireich, J. Cortes, S. Lerner, and M. J. Keating. 2001. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J. Clin. Oncol. 19: 2165-2170.
57. Kinoshita, T., H. Nagai, T. Murate, and H. Saito. 1998. CD20-negative relapse in B-cell lymphoma after treatment with Rituximab. J. Clin. Oncol. 16: 3916.
58. Davis, T. A., D. K. Czerwinski, and R. Levy. 1999. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin. Cancer Res. 5: 611-615.
59. Jilani, I., S. O'Brien, T. Manshuri, D. A. Thomas, V. A. Thomazy, M. Imam, S. Naeem, S. Verstovsek, H. Kantarjian, F. Giles, et al. 2003. Transient downmodulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood 102: 3514-3520.
60. Lim, S. H., A. T. Vaughan, M. Ashton-Key, E. L. Williams, S. V. Dixon, H. T. Chan, S. A. Beers, R. R. French, K. L. Cox, A. J. Davies, et al. 2011. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood 118: 2530-2540.
61. Herter, S., F. Herting, O. Mundigl, I. Waldhauer, T. Weinzierl, T. Fauti, G. Muth, D. Ziegler-Landesberger, E. Van Puijenbroek, S. Lang, et al. 2013. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol. Cancer Ther. 12: 2031-2042.
62. Dalle, S., L. Reslan, T. Besseyre De Horts, S. Herveau, F. Herting, A. Plesa, T. Friess, P. Umana, C. Klein, and C. Dumontet. 2011. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Mol. Cancer Ther. 10: 178-185.
63. Niederfellner, G., A. Lammens, O. Mundigl, G. J. Georges, W. Schaefer, M. Schwaiger, A. Franke, K. Wiechmann, S. Jenewein, J. W. Slootstra, et al. 2011. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood 118: 358-367.
64. Rafiq, S., J. P. Butchar, C. Cheney, X. Mo, R. Trotta, M. Caligiuri, D. Jarjoura, S. Tridandapani, N. Muthusamy, and J. C. Byrd. 2013. Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties. J. Immunol. 190: 2702-2711
65. Peipp, M., J. J. Lammerts Van Bueren, T. Schneider-Merck, W. W. Bleeker, M. Dechant, T. Beyer, R. Repp, P. H. Van Berkel, T. Vink, J. G. Van De Winkel, et al. 2008. Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood 112: 2390-2399.
66. Sehn, L. H., A. Goy, F. C. Offner, G. Martinelli, J. Friedberg, S. F. Lasserre, G. Fine, and O. W. Press. 2011. Randomized phase II trial comparing GA101 (obinutuzumab) with rituximab in patients with relapsed CD201 indolent B-cell non-Hodgkin lymphoma: Preliminary analysis of the GAUSS Study. Blood 118: 269 (Abstr.).
67. Goede, V., K. Fischer, R. Busch, A. Engelke, B. Eichhorst, C. M. Wendtner, T. Chagorova, J. De La Serna, M. S. Dilhuydy, T. Illmer, et al. 2014. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N. Engl. J. Med. 370: 1101-1110.
68. Kohrt, H. E., R. Houot, M. J. Goldstein, K. Weiskopf, A. A. Alizadeh, J. Brody, A. Müller, R. Pachynski, D. Czerwinski, S. Coutre, et al. 2011. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 117: 2423-2432.
69. Wolach, O., O. Shpilberg, and M. Lahav. 2012. Neutropenia after rituximab treatment: New insights on a late complication. Curr. Opin. Hematol. 19: 32-38.
70. Ghielmini, M., S. F. Schmitz, S. B. Cogliatti, G. Pichert, J. Hummerjohann, U. Waltzer, M. F. Fey, D. C. Betticher, G. Martinelli, F. Peccatori, et al. 2004. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly 3 4 schedule. Blood 103: 4416-4423.
71. Carson, K. R., A. M. Evens, E. A. Richey, T. M. Habermann, D. Focosi, J. F. Seymour, J. Laubach, S. D. Bawn, L. I. Gordon, J. N. Winter, et al. 2009. Progressive multifocal leukoencephalopathy after rituximab therapy in HIVnegative patients: A report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113: 4834-4840.
72. Dunn, G. P., A. T. Bruce, H. Ikeda, L. J. Old, and R. D. Schreiber. 2002. Cancer immunoediting: From immunosurveillance to tumor escape. Nat. Immunol. 3: 991-998.
73. Zitvogel, L., L. Apetoh, F. Ghiringhelli, and G. Kroemer. 2008. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8: 59-73